KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Equity Average (2016 - 2026)

Bristol Myers Squibb has reported Equity Average over the past 17 years, most recently at $19.3 billion for Q1 2026.

  • Quarterly Equity Average rose 153.49% to $19.3 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $19.3 billion through Mar 2026, up 153.49% year-over-year, with the annual reading at $16.7 billion for FY2025, 149.78% up from the prior year.
  • Equity Average was $19.3 billion for Q1 2026 at Bristol Myers Squibb, up from $18.5 billion in the prior quarter.
  • Over five years, Equity Average peaked at $19.3 billion in Q1 2026 and troughed at -$22.6 billion in Q1 2024.
  • The 5-year median for Equity Average is $173.0 million (2025), against an average of -$1.1 billion.
  • Year-over-year, Equity Average plummeted 4474.62% in 2024 and then surged 3094.18% in 2025.
  • A 5-year view of Equity Average shows it stood at -$1.1 billion in 2022, then surged by 1356.93% to $13.3 billion in 2023, then crashed by 43.0% to $7.6 billion in 2024, then soared by 143.84% to $18.5 billion in 2025, then increased by 3.96% to $19.3 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Equity Average are $19.3 billion (Q1 2026), $18.5 billion (Q4 2025), and $9.3 billion (Q3 2025).